Comparative Pharmacology
Head-to-head clinical analysis: BUSULFEX versus CARBOPLATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUSULFEX versus CARBOPLATIN.
BUSULFEX vs CARBOPLATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Busulfan is a bifunctional alkylating agent that cross-links DNA, leading to inhibition of DNA replication and cell death.
Carboplatin forms platinum-DNA adducts, causing intrastrand crosslinks and G2/M cell cycle arrest, leading to apoptosis.
Busulfan 0.8 mg/kg IV every 6 hours for 4 days (total 16 doses) or 3.2 mg/kg IV once daily for 4 days, based on ideal body weight or actual body weight (whichever is lower).
IV infusion over 15-60 minutes, target AUC 4-6 using Calvert formula (dose = target AUC × (GFR + 25)). Adults: typical initial dose 400 mg/m² every 4 weeks or AUC 5-6 every 3-4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5 hours (range: 1.5-4.0 hours) in adults. In children, half-life is shorter (~1.4 hours). Clinically, this supports high-dose, fractionated dosing regimens (e.g., every 6 hours) to maintain therapeutic levels.
Clinical Note
moderateCarboplatin + Digoxin
"Carboplatin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCarboplatin + Digitoxin
"Carboplatin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCarboplatin + Deslanoside
"Carboplatin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCarboplatin + Acetyldigitoxin
"Carboplatin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: 2.6-5.9 hours in adults with normal renal function. In patients with creatinine clearance <60 mL/min, half-life is prolonged (up to 17-26 hours). Clinically, dosing adjustments are required based on Calvert formula using glomerular filtration rate.
Primarily hepatic metabolism via conjugation with glutathione, followed by renal excretion of metabolites. Less than 2% of the parent drug is excreted unchanged in urine. Fecal excretion is negligible.
Renal: ~65% of platinum excreted in urine within 24 hours, primarily as unchanged carboplatin; ~32% as metabolites. Biliary/fecal excretion is minimal (<6%).
Category C
Category D/X
Alkylating Agent
Alkylating Agent